Combined use of cyclosporine in the treatment of Stevens–Johnson syndrome/toxic epidermal necrolysis

The exact efficacy of cyclosporine in the treatment of Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) still needs evidence from more clinical data. This study was designed to compare the effectiveness and side‐effects of combined use of cyclosporine in the treatment TEN with glucoco...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2022-06, Vol.49 (6), p.629-636
Main Authors: Yu, Rentao, Chen, Shuang, Pan, Yun, Ma, Chunrong, Hu, Li, Chen, Aijun, Wei, Bin
Format: Article
Language:English
Subjects:
body surface area detached
Clinical outcomes
cyclosporine
Cyclosporins
Disseminated infection
Drug dosages
Glucocorticoids
Immunoglobulin G
Inhibitor drugs
Intravenous administration
Patients
Risk factors
SCORTEN
Side effects
Skin diseases
Stevens–Johnson syndrome
Toxic epidermal necrolysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The exact efficacy of cyclosporine in the treatment of Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) still needs evidence from more clinical data. This study was designed to compare the effectiveness and side‐effects of combined use of cyclosporine in the treatment TEN with glucocorticoids (GC)/i.v. immunoglobulin G (IVIG). A total of 46 patients with SJS/TEN were enrolled and classified into two groups based on the therapeutic drugs used. Clinical characteristics, interventions, outcomes, and disease progressions were collected and compared between the two groups. In our cohort, seven patients eventually died and the overall fatality rate was 15.2%, but there was no difference between the two groups (p = 0.557). On discharge, the median SCORe of Toxic Epidermal Necrosis (SCORTEN) fell from 2.0 at admission to 1.0 and the median body surface area detached fell from 32.0% at admission to 9.5%. Patients in the cyclosporine group had a higher rate of re‐epithelialized area than patients in the non‐cyclosporine group (p 
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.16369